BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis

被引:221
|
作者
Li, Carol [1 ]
Lee, Kathleen C. [1 ]
Schneider, Eric B. [1 ]
Zeiger, Martha A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Endocrine Surg Sect, Baltimore, MD 21287 USA
来源
基金
美国国家卫生研究院;
关键词
ASPIRATION BIOPSY SPECIMENS; LYMPH-NODE METASTASIS; TALL-CELL VARIANT; BRAF(V600E) MUTATION; HIGH PREVALENCE; GENE MUTATION; HIGH-RISK; CARCINOMA; RECURRENCE; EXPRESSION;
D O I
10.1210/jc.2012-2104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is conflicting literature regarding the association of the BRAF V600E mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC). Nevertheless, some propose that BRAF status be incorporated into the management of patients with PTC, specifically recommendations regarding lymph node dissection. We therefore performed a meta-analysis to examine the relationship between BRAF and clinicopathological features of PTC. Methods: A literature search was performed within PubMed and EMBASE databases using the following Medical Subject Headings (MeSH) and keywords: "braf," "mutation," "thyroid," "neoplasm(s)," "tumor," "cancer," and "carcinoma." Individual study-specific odds ratios and confidence intervals were calculated, as were Mantel-Haenszel pooled odds ratios for the combined studies. Results: Thirty-two studies including 6372 patients were reviewed. BRAF mutation was associated with lymph node metastases (LNM), advanced stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC. There was no association with age or vascular invasion. Only two studies were prospective; nine included consecutive patients, whereas one included randomly selected patients; and only two included patients who had undergone routine central lymph node dissection and were thus evaluable for the presence of LNM. Conclusion: Meta-analysis found that BRAF mutation is associated with LNM, stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant PTC in PTC. However, almost all studies were retrospective and only two of 32 included patients who had undergone routine central lymph node dissection, emphasizing the need for well-designed studies to appropriately examine this association before making important clinical decisions. (J Clin Endocrinol Metab 97: 4559-4570, 2012)
引用
收藏
页码:4559 / 4570
页数:12
相关论文
共 50 条
  • [31] Braf V600E mutation analysis in low and intermediate risk papillary thyroid carcinoma
    Lopez Villar, I.
    Navarro Martinez, T.
    Jane Soler, P.
    Bonilla Plaza, J.
    Martinez Lorca, A.
    Perez Iruela, J.
    Orduna Diez, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S71 - S72
  • [32] BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
    Lai, Hon-Fan
    Hang, Jen-Fan
    Kuo, Po-Chung
    Kuo, Chin-Sung
    Yao, San-Fan
    Chen, Jui-Yu
    Lee, Chen-Hsen
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (05) : 3495 - 3501
  • [33] Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients
    Shin, Mi Kyung
    Kim, Jeong Won
    Min, Soo Kee
    Lee, Dong Jin
    Kim, Jin Hwan
    Lee, Seung Chul
    Chung, Bong Wha
    Ju, Young Su
    ONCOLOGY LETTERS, 2015, 10 (03) : 1882 - 1888
  • [34] BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
    Hon-Fan Lai
    Jen-Fan Hang
    Po-Chung Kuo
    Chin-Sung Kuo
    San-Fan Yao
    Jui-Yu Chen
    Chen-Hsen Lee
    Annals of Surgical Oncology, 2024, 31 : 3495 - 3501
  • [35] TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis
    Chunping Liu
    Zeming Liu
    Tianwen Chen
    Wen Zeng
    Yawen Guo
    Tao Huang
    Scientific Reports, 6
  • [36] Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer
    Schumm, Max A.
    Nikiforov, Yuri E.
    Nikiforova, Marina N.
    Wald, Abigail, I
    Tseng, Chi-Hong
    Smooke-Praw, Stephanie
    Wu, James X.
    Yeh, Michael W.
    Livhits, Masha J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [37] TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis
    Liu, Chunping
    Liu, Zeming
    Chen, Tianwen
    Zeng, Wen
    Guo, Yawen
    Huang, Tao
    SCIENTIFIC REPORTS, 2016, 6
  • [38] BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis
    Yusof, Mohd Nazzary Mamat
    Ch'ng, Ewe Seng
    Rahman, Nawal Radhiah Abdul
    CANCERS, 2022, 14 (22)
  • [39] The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis
    Li, Jianhua
    Zhang, Shuijun
    Zheng, Shouhua
    Zhang, Danhua
    Qiu, Xinguang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (12): : 22246 - U565
  • [40] BRAF V600E Mutation In Papillary Thyroid Cancer: Its Influence On Radioiodine Postsurgical Therapy - Preliminary Results
    Dominguez-Ayala, M.
    Minguez-Gabina, P.
    Exposito Rodriguez, A.
    Ortiz de Zarate, E. Rodeno
    Gutierrez Rodriguez, T.
    Barrios Trevino, B.
    Paja Fano, M.
    Gomez Palacios, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S157 - S157